# Symbiotic-GU-06 (NCT07421700)

> Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

No report yet. It can be ordered.

- Drugs tested: PF-08634404; PF-08634404 plus enfortumab vedotin
- Indication: locally advanced or metastatic urothelial cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07421700
- Phase: PHASE1, PHASE2
- Status: RECRUITING
- Sponsor: Pfizer
- Conditions: Urothelial Cancer; Advanced/Metastatic Urothelial Cancer; Urothelial Carcinoma
- Interventions: PF-08634404; Enfortumab Vedotin
- Enrollment: 132
- Primary outcome: Confirmed Objective Response Rate (ORR) by investigator
- Primary outcome: Number of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
- Primary outcome: Number of participants with dose limiting toxicity (DLT) in Part 1 of Cohort B

## Indexed commentary on Symbiotic-GU-06 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=symbiotic-gu-06-nct07421700